1. ScholarBank@NUS

XXX Folefac Aminkeng

rp62345

Collaboration Map View Statistics Email Alert RSS Feed

Profile

Full Name
XXX Folefac Aminkeng
(not current staff)
Main Affiliation
 
Faculty
 
Email
mdcfa@nus.edu.sg
 

Publications

Refined By:
Date Issued:  [2020 TO 2024]

Results 1-9 of 9 (Search time: 0.005 seconds).

Issue DateTitleAuthor(s)
1Aug-2023An Introductory Tutorial on Cardiovascular Pharmacogenetics for Healthcare ProvidersOni-Orisan, Akinyemi; Tuteja, Sony; Hoffecker, Glenda; Smith, D Max; Castrichini, Matteo; Crews, Kristine R; Murphy, William A; Nguyen, Nam HK; Huang, Yimei; Lteif, Christelle; Friede, Kevin A; Tantisira, Kelan; XXX Folefac Aminkeng ; Voora, Deepak; Cavallari, Larisa H; Whirl-Carrillo, Michelle; Duarte, Julio D; Luzum, Jasmine A
228-Jan-2022Cytokine Release Syndrome in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Case Series of 25 Patients and Review of the LiteratureTay, Sen Hee ; Toh, Michelle Min Xuan ; Thian, Yee Liang ; Vellayappan, Balamurugan A ; Fairhurst, Anna-Marie ; Chan, Yiong Huak ; Aminkeng, Folefac ; Bharwani, Lavina D; Huang, Yiqing; Mak, Anselm ; Wong, Alvin Seng Cheong
3Sep-2022Factors Predictive of Primary Resistance to Immune Checkpoint Inhibitors in Asian Patients with Advanced NSCLCHuang, Y; Zhao, JJ; Soon, YY; Kee, A; Tay, SH; Aminkeng, F ; Ang, Y; Wong, A; Goh, BC; Soo, R 
412-May-2023Factors Predictive of Primary Resistance to Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung CancerHuang, Yiqing; Zhao, Joseph J; Soon, Yu Yang; Kee, Adrian; Tay, Sen Hee; Aminkeng, Folefac ; Ang, Yvonne; Wong, Alvin SC; Bharwani, Lavina D; Goh, Boon Cher; Soo, Ross A 
51-Mar-2021Neutrophil-to-Lymphocyte Ratio Predicts Development of Immune-Related Adverse Events and Outcomes from Immune Checkpoint Blockade: A Case-Control StudyLee, Pei Yi; Oen, Kellynn Qi Xuan; Lim, Grace Rui Si; JUANDA LEO HARTONO ; MARK DHINESH MUTHIAH ; Huang, Daniel Q; Teo, Felicia Su Wei; LI YUNKAI ANDREW ; Mak, A. ; Chandran, Nisha Suyien; CHRIS TAN LIXIAN ; Yang, Peiling; Tai, E.S. ; Ng, Kay Wei Ping; JOY VIJAYAN ; Chan, Yee Cheun; TAN LI LING ; LEE BENG HUAT, MARTIN ; Chua, Horng Ruey; HONG WEI ZHEN ; YAP ENG SOO ; Lim, Dawn K; YUEN YEW SEN ; Chan, Y.H. ; FOLEFAC AMINKENG ; Wong, Alvin Seng Cheong; Huang, Yiqing; TAY SEN HEE 
61-Jun-2022Pharmacogenomic prediction of immune-related adverse events from immune checkpoint inhibitors among Asian patientsHuang, Yiqing; Aminkeng, Folefac ; Wong, Alvin SC; Tay, Sen Hee ; Zhao, Joseph J; Ang, Yvonne; Soo, Ross A ; Goh, Boon Cher 
730-Sep-2022Real-world experience of consolidation durvalumab after concurrent chemoradiotherapy in stage III non-small cell lung cancerHuang, Yiqing; Zhao, Joseph J; Soon, Yu Yang ; Wong, Alvin; Aminkeng, Folefac ; Ang, Yvonne; Asokumaran, Yugarajah; Low, Jia Li; Lee, Matilda; Choo, Joan RE; Chan, Gloria; Kee, Adrian ; Tay, Sen Hee ; Goh, Boon Cher ; Soo, Ross A 
813-Oct-2021Risk factors for immune-related adverse events from anti-PD-1 or anti-PD-L1 treatment in an Asian cohort of nonsmall cell lung cancer patientsHuang, Yiqing; Soon, Yu Yang ; Aminkeng, Folefac ; Tay, Sen Hee ; Ang, Yvonne; Kee, Adrian CL ; Goh, Boon Cher ; Wong, Alvin SC; Soo, Ross A 
9Mar-2021Risk Factors for Immune-Related Adverse Events from Anti-PD-1/PD-L1 Treatment in an Asian Cohort of NSCLC PatientsHuang, Y; Soon, YY; Aminkeng, F ; Tay, SH; Ang, Y; Goh, BC; Wong, A; Soo, RA